drugset / Trial / NCT05565807
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
NaSequentialOpen-labelTreatment
Summary
This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2023-02-09
- Primary completion
- 2026-12-31
- Completion
- 2028-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STI-6129 | Other / unclassified | 0.25 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 0.5 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 0.67 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 0.88 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 1.18 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 1.56 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 2.08 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 2.77 mg/kg | Intravenous |
| Subject | STI-6129 | Other / unclassified | 3.68 mg/kg | Intravenous |